Comparable stake leader
SUVRETTA CAPITAL MANAGEMENT, LLC
SEC ownership of MARINUS PHARMACEUTICALS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001267813.
Disclosed value leader
SUVRETTA CAPITAL MANAGEMENT, LLC
Comparable rows
3/9
Latest evidence
07 Feb 2025
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
SUVRETTA CAPITAL MANAGEMENT, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
3 of 9
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
SUVRETTA CAPITAL MANAGEMENT, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
07 Feb 2025
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001267813
- Issuer location
- Radnor, PA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of MARINUS PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
SUVRETTA CAPITAL MANAGEME...
Disclosed value leader
SUVRETTA CAPITAL MANAGEME...
Comparable rows
3/9
Latest evidence
07 Feb 2025
13D/G
3/4/5
Lead comparable stake: 5.5%
6 rows are not safely comparable across share classes.
13D/G row: SUVRETTA CAPITAL MANAGEMENT, LLC
Showing 1-8 of 9 holder rows.
Quick read
SUVRETTA CAPITAL MANAGEMENT, LLC leads the comparable SEC ownership view at 5.5%.
3 of 9 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens SUVRETTA CAPITAL MANAGEMENT, LLC's linked filing trail.
Comparable ownership
Top 3
SUVRETTA CAPITAL MANAGEMENT, LLC
5.5%
VANGUARD GROUP INC
4.7%
TANG CAPITAL PARTNERS LP
3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 9 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13D/G
|
5.5%
|
$1,662,437
3,022,612 shares
|
+$504,541 | 07 Feb 2025 |
| VANGUARD GROUP INC |
13D/G
The Vanguard Group
|
4.7%
|
$1,428,222
2,596,768 shares
|
$0 | 31 Dec 2024 |
| TANG CAPITAL PARTNERS LP |
13D/G
TANG CAPITAL MANAGEMENT, LLC
|
3%
|
$903,070
1,641,945 shares
|
$0 | 31 Dec 2024 |
| Sarah B. Noonberg |
3/4/5
Director
|
—
mixed-class rows
|
$60,348
24,550 shares
mixed-class rows
|
— | 18 Jun 2024 |
| Nicole Vitullo |
3/4/5
Director
|
—
mixed-class rows
|
$57,527
18,817 shares
mixed-class rows
|
— | 04 Feb 2022 |
| Sara Nochur |
3/4/5
Director
|
—
mixed-class rows
|
$56,710
23,700 shares
mixed-class rows
|
— | 18 Jun 2024 |
| Charles Austin |
3/4/5
Director
|
—
mixed-class rows
|
$52,118
22,627 shares
mixed-class rows
|
— | 18 Jun 2024 |
| Michael R. Dougherty |
3/4/5
Director
|
—
mixed-class rows
|
$29,576
15,687 shares
mixed-class rows
|
— | 04 Feb 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 12 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to MARINUS PHARMACEUTICALS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Largest Forms 3/4/5 holder
Sarah B. Noonberg
Net 12M change
$0
Latest report
07 Feb 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Sarah B. Noonberg | Director | $60,348 | Mixed | 18 Jun 2024 | ||
| Nicole Vitullo | Director | $57,527 | Mixed | 04 Feb 2022 | ||
| Sara Nochur | Director | $56,710 | Mixed | 18 Jun 2024 | ||
| Charles Austin | Director | $52,118 | Mixed | 18 Jun 2024 | ||
| Michael R. Dougherty | Director | $29,576 | Mixed | 04 Feb 2022 | ||
| Santiago Arroyo | Director | $24,558 | Mixed | 04 Feb 2022 | ||
| Joseph Hulihan | Chief Medical Officer | $0 | Mixed | 07 Feb 2025 | ||
| Elan Ezickson | Director | $0 | Mixed | 07 Feb 2025 | ||
| Marvin Johnson | Director | $0 | Mixed | 07 Feb 2025 | ||
| Christina Shafer | Chief Commercial Officer | $0 | Mixed | 07 Feb 2025 | ||
| Scott Braunstein | CHAIRMAN AND CEO, Director | $0 | Mixed | 14 Aug 2024 | ||
| Christine Berni Silverstein | Director | $0 | Mixed | 07 Feb 2025 | ||
| Martha E. Manning | Svp, Gen. Counsel & Corp. Sec. | $0 | Mixed | 07 Feb 2025 | ||
| Timothy M. Mayleben | Director | $0 | Mixed | 07 Feb 2025 | ||
| Seth H. Z. Fischer | Director | $0 | Mixed | 07 Feb 2025 | ||
| Steven Pfanstiel | Cfo And Coo | $0 | Mixed | 07 Feb 2025 |
Recent insider transactions for MARINUS PHARMACEUTICALS, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.